Recent Updates
Recently added Catalysts

DisCoVisc, DuoVisc, BioVisc, Healon5, Amvisc Plus

Phase 3

Cataracts | Unknown | Ophthalmology |Alcon Inc.|Last Updated: Jul 30, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLED
Total Trials1
Total Enrollment173
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00732225DisCoVisc Comparative EvaluationPHASE3 COMPLETED 173May 1, 2007 -Jul 30, 20101 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent Loss of Endothelial Cells
2 months following surgery

Percentage of corneal endothelial cells lost 2 months after surgery as compared to the number of corneal endothelial cells measured before the operation. Corneal Endothelial Cells are measured by counting the number of cells on an image taken by specular microscope.

Secondary Endpoints
Aqueous Signs - Corneal Edema
1 day after surgery
Aqueous Signs - Aqueous Flare
1 day following surgery
Aqueous Signs - Aqueous Cells
1 day following surgery
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
DisCoViscACTIVE_COMPARATORAlcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
DuoViscACTIVE_COMPARATORAlcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
BioViscACTIVE_COMPARATORSophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
Healon5ACTIVE_COMPARATORAMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
Amvisc PlusACTIVE_COMPARATORBausch \& Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
Interventions
NameTypeDescription
DisCoViscDEVICEDisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
DuoViscDEVICEDuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
BioViscDEVICEBioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
Healon5DEVICEHealon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
Amvisc PlusDEVICEAmvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
Unlock Study Design Details
Eligibility Criteria
Age Range49 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Unilateral operable cataracts Exclusion Criteria: * Preoperative Endothelial Cell Count (ECC) ≤1500 cells/mm2 * Intraocular Pressure (IOP) \> 21 * History of ocular inflammation * Systemic or ocular diseases affecting corneal endothelium

Countries:United States
Unlock Eligibility Criteria